News Kamada Ltd.

Stocks

KMDA

IL0010941198

Pharmaceuticals

Delayed TEL AVIV STOCK EXCHANGE 11:11:29 2026-10-26 EDT			5-day change	1st Jan Change
2,415.00 ^ILa	+0.75%		+2.11%	+6.86%

10-06	Kamada Launches Ustekinumab, Enoxaparin Biosimilars in Israel	MT
10-06	Kamada Ltd. Announces Expansion of Biosimilars Portfolio with Launch of Two Additional Products in Israel	CI

All News

Mentions Relevance

10-06	Kamada Launches Ustekinumab, Enoxaparin Biosimilars in Israel	MT
10-06	Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel	AQ
10-06	Kamada Ltd. Announces Expansion of Biosimilars Portfolio with Launch of Two Additional Products in Israel	CI
09-17	Kamada Confirms Sufficient Kedrab Supply to Meet Increased Demand in the United States	CI
09-17	Kamada Maintains 'Sufficient' KedRAB Supply, Production Capacity Amid Increasing Rabies Exposures in US	MT
09-17	CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand	AQ
09-10	Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
09-06	Kamada : Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders	PU
09-03	Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders	AQ
09-03	Kamada Ltd. Obtains Israel Tax Authority Ruling on Withholding Tax Procedures for $9.8 Million Cash Dividend to Shareholders	CI
08-18	Kamada Declares Cash Dividend of $0.17 per Share, the Company Reported Record-High Revenue and Profitability for First Six Months of 2026	AQ
08-17	Kamada Lowers Quarterly Dividend to $0.17 a Share; Payable Sept. 17 to Holders of Record Aug. 27	MT
08-17	Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026	AQ
08-17	Kamada Ltd. Declares Cash Dividend, Payable on September 17, 2026	CI
08-12	Kamada Ltd., Q2 2026 Earnings Call, Aug 12, 2026
08-12	Kamada Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	Kamada's Finance Chief Chaime Orlev to Step Down	MT
08-12	Kamada: Q2 Earnings Snapshot	AQ
08-12	Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance	AQ
08-12	Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2026	CI
08-12	Kamada Announces Planned Transition of Chief Financial Officer	AQ
08-12	Chaime Orle Plans to Resign as Chief Financial Officer of Kamada Ltd, Effective December 31, 2026	CI
08-05	Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026	AQ
07-20	Kamada Ltd Announces Three-Year USD 50 Million Supply Agreement To Supply Plasma To Biopharmaceutical Company Focused On Plasma-Derived Therapies	CI
07-20	Kamada Signs $50 Million Plasma Supply Agreement With Biopharmaceutical Firm	MT